ERBB2 and urinary bladder cancer: For example, GEC showed an especially high proportion of predicted subclonal ERBB2 mutations across domains (25.2% ECD, 42.9% TMD, 26.0% KD, and 29.8% other) and a sizable proportion of ECD mutations in bladder cancer (23.8%) also seemed to be subclonal.